• PMO and project management for a global SAP S/4 HANA transformation in Commercial, Life Science, with focus onentry readiness, early deployment, and change  management, incl. workshop design and stakeholder management
• Consulting and interim manangement e.g. SME company valuation for a M&A divesture, business process management (BPM), data analysis, and competitive analysis prior to an ERP system introduction
• Portfolio management, coaching and mentoring for a portfolio of five start-ups in the  field of Digital Retail, Medtech and Genomics

• Implementation of Merck?s Digital Sales program RS EMEA, starting from a pilot with 35 inside sales and 90m in 2018 to 400+ digitally-enabled sales professionals in 2021 (Palantir Redox, LinkedIn Sales Navigator, SFDC, EveryoneSocial)
• Digital transformation of the full SLS EMEA commercial organization incl. marketing- and specialist functions, growing the community to 550+ user with a digitally-enabled sales volume of 1.1b (+129m financial impact FY22)
• Roll-out of Merck?s first Account-based Sales & Marketing (ABM) pilot EEMEA with 3 product groups and 35 target accounts in Academia, Pharma and CDMO across Eastern Europe (+1.1m financial impact 03-12.2022)

• Strategy development & implementation across APAC7 incl. China, India, Australia, Japan and S. Korea
• CRM/SFDC, Pricing, Market- & Competitive Intelligence (with 06/2017)
• Operational Excellence; SLI (Service Level Improvement) project APAC-wide roll-out (07/2017 onwards)

• Re-alignment of the WEU field sales organization post Merck Millipore acquisition including As-is analysis, new Go-ToMarket approach plus territory design and implementation
• Preparation and realization of a strategic wargame exercise in the context of a pre-merger preparation
• Post-merger integration incl. APAC-/ EMEA-wide portfolio roll-out of a medium-sized Biotech
• Development and implementation of an European Biosimilar counter strategy task force (BU Fertility) 

• Global P&L responsibililty for Merck?s fine chemicals and CMO business ?Organics & Peptides? with 30m+ turnover (+4.5m FY10 vs. 09)
• Lead a team of 3 product managers and 7 inside sales managers, serving global B2B Pharma and Chemical accounts, both directly and through Merck?s global subsidiaries
• Operational product management (+6000 products, +30k SKUs) of all Marketing & Sales activities e.g. sales cooperations with a major European specialty provider and global roll-out/expansion of Merck?s Pharma non-GMP product line

• Implementation of Merck India's growth strategy for the Chemical and pharmaceutical divisions: doubled total company turnover in 4 years, doubled Chemical division turnover in 3 years (+60m FY10 vs. FY06; +30m FY09 vs. 06)
• Built and lead a team of 10 professionals to continuously monitor, update and review progress of the previously developed growth strategy as well as its divisional sub-strategies
• Planned and coordinated +30 operational projects to support strategic initiatives both for the Chemical and Pharmaceutical divisions e.g. 4 major SFE programs (+750 FTE Pharmaceutical division, +150 FTE Chemical division), gross margin improvement (+1.5m) and inventory mgmt optimization (+1m net CF)

Coordinated major international projects with focus on Sales, Marketing, and Strategy Development

• Development of Merck India?s overall growth strategy 2006/2011 (3 divisions, +250m)
• Review and realigment of Merck?s Pharma strategy South East Asia (7 countries, +120m)
• Optimization of Merck?s global Pharma mfg. network (3 divisions, +20 sites, +80m savings identified)

• Restructuring of the sales organisation for a major German health insurance company including planning, workers council negotiations and implementation
• Analysis and implementation of a direct costing-based Pricing & Sales model for a European interlining manufacturer
• Reorganization and interim management of e-Commerce and mail order business for a major German motorcyle equipment manufacturer
• Planned, conducted, and published Droege & Comp. s biotechnology report 2003 with +60 leading German Biotech companies incl. press coverage by Financial Times, Germany, and Frankfurter Allgemeine Zeitung

• Ph.D Thesis: on request
• Evaluated emerging, recombinant technologies as part of the new product development (NPD) process with Roche Molecular Biochemicals, e.g. DNA chip, Microspot, LightCycler qRT-PCR and cell-free protein bioreactor
• Founded an interdivisional research group with (on request) Ph.D. students, developed an internal spin-off concept